Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010-2016.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In England and Wales, replacement of childhood 7-valent pneumococcal conjugate vaccine (PCV7) with a 13-valent vaccine (PCV13) in 2010 was associated with a significant reduction in PCV13-serotype invasive pneumococcal disease (IPD), with a small increase in IPD due to non-vaccine serotypes. Here, we describe the clinical presentation, comorbidity prevalence, serotype distribution and outcomes of childhood IPD during the first 6 years after PCV13 introduction.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Pediatr. Infect. Dis. J.

Title: The Pediatric infectious disease journal

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1532-0987

ISSN (Print): 0891-3668

Publication date (Electronic): July 2018

Volume: 37

Issue: 7

Affiliations

[1 ] From the Immunisation Department, Public Health England, London, United Kingdom.

[2 ] Respiratory and Vaccine Preventable Bacterial Reference Unit (RVPBRU), Public Health England, London, United Kingdom.

[3 ] Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom.

[4 ] Statistics, Modelling and Economics Department, Public Health England, London, United Kingdom.

[5 ] Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.

Article

Publisher Item ID: 00006454-201807000-00017

DOI: 10.1097/INF.0000000000001845

PubMed ID: 29889811

SO-VID: a8f225b9-f003-4004-a457-27f0393550c7

History

Data availability:

Comments

Comment on this article

scite_

Cited by 10

See all cited by